{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:55:34Z","timestamp":1793739334837,"version":"4.6.1"},"reference-count":100,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor Xa (FXa) have replaced warfarin and other vitamin K antagonists (VKAs) for most indications requiring long-term anticoagulation. In many clinical situations, DOACs are as effective as VKAs, cause less bleeding, and do not require laboratory monitoring. However, because DOACs target proteases that are required for hemostasis, their use increases the risk of serious bleeding. Concerns over therapy-related bleeding undoubtedly contribute to undertreatment of many patients who would benefit from anticoagulation therapy. There is considerable interest in the plasma zymogen factor XI (FXI) and its protease form factor XIa (FXIa) as drug targets for treating and preventing thrombosis. Laboratory and epidemiologic studies support the conclusion that FXI contributes to venous and arterial thrombosis. Based on 70 years of clinical observations of patients lacking FXI, it is anticipated that drugs targeting this protein will cause less severe bleeding than warfarin or DOACs. In phase 2 studies, drugs that inhibit FXI or FXIa prevent venous thromboembolism after total knee arthroplasty as well as, or better than, low molecular weight heparin. Patients with heart disease on FXI or FXIa inhibitors experienced less bleeding than patients taking DOACs. Based on these early results, phase 3 trials have been initiated that compare drugs targeting FXI and FXIa to standard treatments or placebo. Here, we review the contributions of FXI to normal and abnormal coagulation and discuss results from preclinical, nonclinical, and clinical studies of FXI and FXIa inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020722","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T07:57:33Z","timestamp":1703404653000},"page":"1465-1475","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Targeting factor XI and factor XIa to prevent thrombosis"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-8014","authenticated-orcid":false,"given":"David","family":"Gailani","sequence":"first","affiliation":[{"name":"1The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-2247","authenticated-orcid":false,"given":"Andras","family":"Gruber","sequence":"additional","affiliation":[{"name":"2Aronora, Inc, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2024041115211859400_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.bmb.a071433","article-title":"Hemostasis: introduction","volume":"33","author":"Macfarlane","year":"1977","journal-title":"Br Med Bull"},{"key":"2024041115211859400_bib2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"issue":"6","key":"2024041115211859400_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"2024041115211859400_bib4","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024041115211859400_bib5","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"Negrier","year":"2019","journal-title":"Blood Rev"},{"key":"2024041115211859400_bib6","first-page":"1968","volume-title":"Hematology: Basic Principles and Practices","author":"Brummel-Ziedins","year":"2023","edition":"8th ed"},{"issue":"19","key":"2024041115211859400_bib7","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1073\/pnas.87.19.7623","article-title":"Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor","volume":"87","author":"Repke","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024041115211859400_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2516.1998.440331.x","article-title":"Newer concepts of blood coagulation","volume":"4","author":"Roberts","year":"1998","journal-title":"Haemophilia"},{"issue":"6","key":"2024041115211859400_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis and vascular development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2024041115211859400_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2024041115211859400_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/978160805469511201010067","volume-title":"Animal Models of Diseases: Translational Medicine Perspective for Drug Discovery and Development","author":"McManus","year":"2012"},{"issue":"9921","key":"2024041115211859400_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"2024041115211859400_bib13","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024041115211859400_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.seminhematol.2014.02.002","article-title":"Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding","volume":"51","author":"Palareti","year":"2014","journal-title":"Semin Hematol"},{"key":"2024041115211859400_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2020.07.012","article-title":"Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: a population being targeted by the implementation of a randomized controlled trial to improve treatment with oral anticoagulants in patients with atrial fibrillation (IMPACT-AFib)","volume":"229","author":"Al-Khatib","year":"2020","journal-title":"Am Heart J"},{"key":"2024041115211859400_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-021-00053-9","article-title":"Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants","volume":"23","author":"Park","year":"2022","journal-title":"Int J Arrhythm"},{"issue":"6","key":"2024041115211859400_bib17","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"2024041115211859400_bib18","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"6","key":"2024041115211859400_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40256-022-00544-7","article-title":"Do oral factor Xa inhibitors have a role in patients with mechanical heart valves?","volume":"22","author":"Li","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"2024041115211859400_bib20","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.jtha.2023.06.036","article-title":"Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials","volume":"21","author":"Eikelboom","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024041115211859400_bib21","doi-asserted-by":"crossref","first-page":"715878","DOI":"10.3389\/fcvm.2021.715878","article-title":"Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines","volume":"8","author":"Pastori","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2024041115211859400_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000001153","article-title":"Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"33","author":"Wu","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"2024041115211859400_bib23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMe2210187","article-title":"Anticoagulation in atrial fibrillation and rheumatic heart disease","volume":"387","author":"Lip","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2024041115211859400_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"issue":"15","key":"2024041115211859400_bib25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2024041115211859400_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V10.2.120.120","article-title":"Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease","volume":"10","author":"Rosenthal","year":"1955","journal-title":"Blood"},{"issue":"6","key":"2024041115211859400_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1055\/a-1528-0499","article-title":"Mechanism, functions, and diagnostic relevance of FXII activation by foreign surfaces","volume":"41","author":"Konrath","year":"2021","journal-title":"Hamostaseologie"},{"key":"2024041115211859400_bib28","first-page":"2125","volume-title":"Hematology: Basic Principles and Practices","author":"Gailani","year":"2023","edition":"8th ed"},{"issue":"15","key":"2024041115211859400_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2024041115211859400_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.hoc.2021.07.012","article-title":"Factor XI deficiency","volume":"35","author":"Lewandowska","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2024041115211859400_bib31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jth.15652","article-title":"Treatment of patients with rare bleeding disorders in the Netherlands: real-life data from the RBiN study","volume":"20","author":"Maas","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024041115211859400_bib32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V65.3.719.719","article-title":"Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds","volume":"65","author":"Ragni","year":"1985","journal-title":"Blood"},{"issue":"1","key":"2024041115211859400_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation-2009.1.97","article-title":"Factor XI deficiency, resolving the enigma","volume":"2009","author":"Bolton-Maggs","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2024041115211859400_bib34","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1016\/S0021-9258(20)89453-8","article-title":"Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces","volume":"266","author":"Naito","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"5022","key":"2024041115211859400_bib35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"issue":"10","key":"2024041115211859400_bib36","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1172\/JCI119412","article-title":"Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis","volume":"99","author":"Von dem Borne","year":"1997","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024041115211859400_bib37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"Gruber","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2024041115211859400_bib38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2008-06-163675","article-title":"Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI","volume":"113","author":"Tucker","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2024041115211859400_bib39","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A\u00a0role for factor XIIa-mediated factor XI activation in thrombus formation in\u00a0vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2024041115211859400_bib40","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1055\/s-0037-1613081","article-title":"FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse","volume":"87","author":"Rosen","year":"2002","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024041115211859400_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024041115211859400_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-012-0186-5","article-title":"Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice","volume":"3","author":"Leung","year":"2012","journal-title":"Transl Stroke Res"},{"issue":"5","key":"2024041115211859400_bib43","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH13-05-0429","article-title":"Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model","volume":"110","author":"van Montfoort","year":"2013","journal-title":"Thromb Haemost"},{"key":"2024041115211859400_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/bloodadvances.2017004879","article-title":"Factor XI contributes to myocardial ischemia-reperfusion injury in mice","volume":"2","author":"Lorentz","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2024041115211859400_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.thromres.2007.03.026","article-title":"In\u00a0vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice","volume":"121","author":"Gui","year":"2007","journal-title":"Thromb Res"},{"issue":"2","key":"2024041115211859400_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2024041115211859400_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"2024041115211859400_bib48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"2024041115211859400_bib49","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2024041115211859400_bib50","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024041115211859400_bib51","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jama.299.11.1306","article-title":"Gene variants associated with deep vein thrombosis","volume":"299","author":"Bezemer","year":"2008","journal-title":"JAMA"},{"issue":"11","key":"2024041115211859400_bib52","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1538-7836.2009.03544.x","article-title":"Genetic variants associated with deep vein thrombosis: the F11 locus","volume":"7","author":"Li","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024041115211859400_bib53","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1160\/th15-06-0459","article-title":"F11 is associated with recurrent VTE in women. A prospective cohort study","volume":"115","author":"Bruzelius","year":"2016","journal-title":"Thromb Haemost"},{"issue":"9","key":"2024041115211859400_bib54","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2024041115211859400_bib55","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"issue":"1-2","key":"2024041115211859400_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0049-3848(02)00190-1","article-title":"Elevated levels of Factor XI are associated with cardiovascular disease in women","volume":"107","author":"Berliner","year":"2002","journal-title":"Thromb Res"},{"issue":"13","key":"2024041115211859400_bib57","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2024041115211859400_bib58","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/jth.12531","article-title":"Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women","volume":"12","author":"Siegerink","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024041115211859400_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2024041115211859400_bib60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"2024041115211859400_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"8","key":"2024041115211859400_bib62","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024041115211859400_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0038-1647467","article-title":"Thromboembolism and bleeding tendency in congenital factor XII deficiency--a study on 74 subjects from 14 Swiss families","volume":"65","author":"L\u00e4mmle","year":"1991","journal-title":"Thromb Haemost"},{"issue":"6","key":"2024041115211859400_bib64","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2007.02530.x","article-title":"Evidence of a U-shaped association between factor XII activity and overall survival","volume":"5","author":"Endler","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024041115211859400_bib65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2009-02-203604","article-title":"Factor XI contributes to thrombin generation in the absence of factor XII","volume":"114","author":"Kravtsov","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024041115211859400_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"2024041115211859400_bib67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.actbio.2019.06.021","article-title":"The blood compatibility challenge. Part 1: blood-contacting medical devices: the scope of the problem","volume":"94","author":"Jaffer","year":"2019","journal-title":"Acta Biomater"},{"issue":"1","key":"2024041115211859400_bib68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0043-1761488","article-title":"The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation","volume":"50","author":"Bartlett","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"2024041115211859400_bib69","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2024041115211859400_bib70","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtha.2022.12.014","article-title":"Titanium is a potent inducer of contact activation: implications for intravascular device","volume":"21","author":"Litvak","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"2024041115211859400_bib71","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood.2022017101","article-title":"Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism","volume":"140","author":"de Jong","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024041115211859400_bib72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0038-1653750","article-title":"Definition of the bleeding tendency in factor XI-deficient kindreds\u2013a clinical and laboratory study","volume":"73","author":"Bolton-Maggs","year":"1995","journal-title":"Thromb Haemost"},{"issue":"7","key":"2024041115211859400_bib73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2024041115211859400_bib74","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024041115211859400_bib75","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"ANT-005 TKA investigators. Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024041115211859400_bib76","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024041115211859400_bib77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"2024041115211859400_bib78","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J\u00a0Med Chem"},{"issue":"6","key":"2024041115211859400_bib79","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024041115211859400_bib80","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"2024041115211859400_bib81","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Capodanno D pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"2024041115211859400_bib82","first-page":"69","article-title":"Development of new anticoagulant in 2023: prime time for anti-factor XI and XIa inhibitors","volume":"48","author":"Bentounes","year":"2023","journal-title":"J\u00a0Med Vasc"},{"issue":"10","key":"2024041115211859400_bib83","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"2024041115211859400_bib84","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10357","key":"2024041115211859400_bib85","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"2024041115211859400_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol"},{"issue":"10333","key":"2024041115211859400_bib87","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"2024041115211859400_bib88","author":"Ruff TR for the AZALEA-TIMI 71 Steering Committee","year":"2023"},{"issue":"16","key":"2024041115211859400_bib89","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A\u00a0multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"2024041115211859400_bib90","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic approach","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"issue":"13","key":"2024041115211859400_bib91","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024041115211859400_bib92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0030-1248722","article-title":"Disorders of hemostasis associated with chronic kidney disease","volume":"36","author":"Jalal","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"2024041115211859400_bib93","unstructured":"Bayer Global. OCEANIC-AF study stopped early due to lack of efficacy\n          . . Accessed 19 November 2023. https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/."},{"issue":"24","key":"2024041115211859400_bib94","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1182\/bloodadvances.2020002456","article-title":"The evolution of factor XI and the kallikrein-kinin system","volume":"4","author":"Ponczek","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024041115211859400_bib95","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1086\/589514","article-title":"Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis","volume":"198","author":"Tucker","year":"2008","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2024041115211859400_bib96","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/IAI.05568-11","article-title":"Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis","volume":"80","author":"Luo","year":"2012","journal-title":"Infect Immun"},{"issue":"20","key":"2024041115211859400_bib97","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood-2011-10-386185","article-title":"Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis","volume":"119","author":"Tucker","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2024041115211859400_bib98","doi-asserted-by":"crossref","first-page":"e0152968","DOI":"10.1371\/journal.pone.0152968","article-title":"Factor XI deficiency alters the cytokine response and activation of contact proteases during polymicrobial sepsis in mice","volume":"11","author":"Bane","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"2024041115211859400_bib99","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/bloodadvances.2018029983","article-title":"Inhibition of contact-mediated activation of factor XI protects baboons against S aureus-induced organ damage and death","volume":"3","author":"Silasi","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2024041115211859400_bib100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2003-12-4195","article-title":"New anticoagulants","volume":"105","author":"Hirsh","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/15\/1465\/2221578\/blood_bld-2023-020722-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/15\/1465\/2221578\/blood_bld-2023-020722-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T11:22:00Z","timestamp":1712834520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/15\/1465\/506712\/Targeting-factor-XI-and-factor-XIa-to-prevent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":100,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,4,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020722","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}